Advanced search
Publication Cover
Future Lipidology Volume 1, 2006 - Issue 6
Journal homepage
286
Views
1
CrossRef citations to date
0
Altmetric
Editorial

Dyslipidemia in HIV infection

Alexandra MangiliTufts University School of Medicine, Nutrition Infection Unit, Jaharis 261, 150 Harrison Avenue, Boston, MA, 02111, USA, Tel.: +1 617 636 3465; Fax.: +1 617 636 3810, E-mail: [email protected]Correspondence[email protected]
&
Christine WankeTufts-New England Medical Center, Department of Medicine, Division of Geographic Medicine & Infectious Diseases, USA, Tel.: +1 617 636 3811; Fax.: +1 617 636 3810, E-mail: [email protected]
Pages 719-728 | Published online: 18 Jan 2017

  • Bergersen BM, Sandvik L, Bruun JN, Tonstad S: Elevated Framingham risk score in HIVpositive patients on highly active antiretroviral therapy: results from a Norwegian study of 721 subjects. Eur. J. Clin. Microbiol. Infect. Dis. 23(8), 625–630 (2004).
  • Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA: Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N. Engl. J.Med. 348(8), 702–710 (2003).
  • Friis-Moller N, Sabin CA, Weber R et al.: Combination antiretroviral therapy and the risk of myocardial infarction. N. Engl. J. Med. 349(21), 1993–2003 (2003).
  • Mangili A, Gerrior J, Tang AM et al.: Cardiovascular risk in a cohort of HIVinfected adults: a study with carotid intimamedia thickness and coronary calcium score. Clin. Infect. Dis. 43(11), 1482–1489 (2006).
  • Jacobson DL, Tang AM, Spiegelman D et al.: Incidence of Metabolic Syndrome in a Cohort of HIV-Infected Adults and Prevalence Relative to the U.S. Population (NHANES). J. Acquir. Immune Defic. Syndr. 43(4), 458–466 (2005).
  • Mulligan K, Grunfeld C, Tai VW et al.: Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J. Acquir. Immune Defic. Syndr. 23(1), 35–43 (2000).
  • Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR: Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J. Clin. Endocrinol. Metab. 74(5), 1045–1052 (1992).
  • Grunfeld C, Kotler DP, Hamadeh R, Tierney A, Wang J, Pierson RN: Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am. J. Med. 86(1), 27–31 (1989).
  • Shor-Posner G, Basit A, Lu Y et al.: Hypocholesterolemia is associated with immune dysfunction in early human immunodeficiency virus-1 infection. Am. J. Med. 94(5), 515–519 (1993).
  • Grinspoon S, Carr A: Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N. Engl. J. Med. 352(1), 48–62 (2005).
  • Riddler SA, Smit E, Cole SR et al.: Impact of HIV infection and HAART on serum lipids in men. JAMA 289(22), 2978–2982 (2003).
  • Grunfeld C, Feingold KR: The role of the cytokines, interferon- and tumor necrosis factor in the hypertriglyceridemia and wasting of AIDS. J. Nutr. 122(Suppl. 3), 749–753 (1992).
  • Grunfeld C, Kotler DP, Shigenaga JK et al.: Circulating interferon- levels and hypertriglyceridemia in the acquired immunodeficiency syndrome. Am. J. Med. 90(2), 154–162 (1991).
  • Asztalos BF, Schaefer EJ, Horvath KV et al.: Protease inhibitor-based HAART, HDL, and CHD-risk in HIV-infected patients. Atherosclerosis 184(1), 72–77 (2006).
  • Echevarria KL, Hardin TC, Smith JA: Hyperlipidemia associated with protease inhibitor therapy. Ann. Pharmacother. 33(7–8), 859–863 (1999).
  • Periard D, Telenti A, Sudre P et al.: Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation 100(7), 700–705 (1999).
  • Petit JM, Duong M, Duvillard L et al.: HIV-1 protease inhibitors induce an increase of triglyceride level in HIV-infected men without modification of insulin sensitivity: a longitudinal study. Horm. Metab. Res. 32(9), 367–372 (2000).
  • Fontas E, van Leth F, Sabin CA et al.: Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J. Infect. Dis. 189(6), 1056–1074 (2004).
  • Young J, Weber R, Rickenbach M et al.: Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study. Antivir. Ther. 10(5), 585–591 (2005).
  • Fisac C, Fumero E, Crespo M et al.: Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine. AIDS 19(9), 917–925 (2005).
  • Purnell JQ, Zambon A, Knopp RH et al.: Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS 14(1), 51–57 (2000).
  • Shafran SD, Mashinter LD, Roberts SE: The effect of low-dose ritonavir monotherapy on fasting serum lipid concentrations. HIV Med. 6(6), 421–425 (2005).
  • Fisac C, Virgili N, Ferrer E et al.: A comparison of the effects of nevirapine and nelfinavir on metabolism and body habitus in antiretroviral-naive human immunodeficiency virus-infected patients: a randomized controlled study. J. Clin. Endocrinol. Metab. 88(11), 5186–5192 (2003).
  • Bongiovanni M, Bini T, Chiesa E, Cicconi P, Adorni F, Monforte DA: Lopinavir/ritonavir versus indinavir/ritonavir in antiretroviral naive HIV-infected patients: immunovirological outcome and side effects. Antiviral Res. 62(1), 53–56 (2004).
  • Antoniou T, Park-Wyllie L, Boyle E: A comparison of dyslipidemias associated with either lopinavir/ritonavir- or indinavir/ritonavir-based antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 37(5), 1666–1667 (2004).
  • Sanne I, Piliero P, Squires K, Thiry A, Schnittman S: Results of a Phase 2 clinical trial at 48 weeks (AI424–007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J. Acquir. Immune Defic. Syndr. 32(1), 18–29 (2003).
  • Murphy RL, Sanne I, Cahn P et al.: Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results. AIDS 17(18), 2603–2614 (2003).
  • Cahn PE, Gatell JM, Squires K et al.: Atazanavir – a once-daily HIV protease inhibitor that does not cause dyslipidemia in newly treated patients: results from two randomized clinical trials. J. Int. Assoc. Physicians AIDS Care (Chic. Ill. ) 3(3), 92–98 (2004).
  • Mobius U, Lubach-Ruitman M, Castro-Frenzel B et al.: Switching to atazanavir improves metabolic disorders in antiretroviral-experienced patients with severe hyperlipidemia. J. Acquir. Immune Defic. Syndr. 39(2), 174–180 (2005).
  • Wanke C, Gerrior J, Hendricks K, McNamara J, Schaefer E: Alterations in lipid profiles in HIV-infected patients treated with protease inhibitor therapy are not influenced by diet. Nutr. Clin. Pract. 20(6), 668–673 (2005).
  • van Leth F, Phanuphak P, Stroes E et al.: Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviraltherapy- naive patients infected with HIV-1. PLoS Med. 1(1), E19 (2004). o Highlights the different impact of the two NNRTIs on lipid profiles. Nevirapine had a somewhat favorable profile compared with efavirenz. 32. Gallant JE, Staszewski S, Pozniak AL et al.: Efficacy and safety of tenofovir DF versus stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 292(2), 191–201 (2004).
  • Jones R, Sawleshwarkar S, Michailidis C et al.: Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone. HIV Med. 6(6), 396–402 (2005).
  • Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285(19), 2486–2497 (2001).
  • Gerrior JL, Neff LM: Nutrition assessment in HIV infection. Nutr. Clin. Care 8(1), 6–15 (2005).
  • Grover SA, Coupal L, Gilmore N, Mukherjee J: Impact of dyslipidemia associated with Highly Active Antiretroviral Therapy (HAART) on cardiovascular risk and life expectancy. Am. J. Cardiol. 95(5), 586–591 (2005).
  • Dolan SE, Hadigan C, Killilea KM et al.: Increased cardiovascular disease risk indices in HIV-infected women. J. Acquir. Immune Defic. Syndr. 39(1), 44–54 (2005).
  • Bard JM, Lassalle R, Capeau J et al.: Association of apolipoproteins C3 and E with metabolic changes in HIV-infected adults treated with a protease-inhibitorcontaining antiretroviral therapy. Antivir. Ther. 11(3), 361–370 (2006).
  • Dube MP, Stein JH, Aberg JA et al.: Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin. Infect. Dis. 37(5), 613–627 (2003).
  • Stein JH: Managing cardiovascular risk in patients with HIV infection. J. Acquir. Immune Defic. Syndr. 38(2), 115–123 (2005).
  • Shah M, Tierney K, Adams-Huet B et al.: The role of diet, exercise and smoking in dyslipidaemia in HIV-infected patients with lipodystrophy. HIV Med. 6(4), 291–298 (2005).
  • Wohl DA, Tien HC, Busby M et al.: Randomized study of the safety and efficacy of fish oil (omega-3 fatty acid) supplementation with dietary and exercise counseling for the treatment of antiretroviral therapy-associated hypertriglyceridemia. Clin. Infect. Dis. 41(10), 1498–1504 (2005).
  • Hellerstein MK, Wu K, McGrath M et al.: Effects of dietary n-3 fatty acid supplementation in men with weight loss associated with the acquired immune deficiency syndrome: relation to indices of cytokine production. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 11(3), 258–270 (1996).
  • Berry J: 13th Conference on Retrovirus and Opportunistic Infections. Metabolics and HIV. Posit. Aware 17(3), 22 (2006).
  • Mangili A, Murman DH, Zampini AM, Wanke CA: Nutrition and HIV infection: review of weight loss and wasting in the era of highly active antiretroviral therapy from the nutrition for healthy living cohort. Clin. Infect. Dis. 42(6), 836–842 (2006).
  • Amorosa V, Synnestvedt M, Gross R et al.: A tale of two epidemics: the intersection between obesity and HIV infection in Philadelphia. J. Acquir. Immune Defic. Syndr. 39(5), 557–561 (2005).
  • Karmon SL, Moore RD, Dobs AS, Keruly J, Barnett S, Cofrancesco J Jr: Body shape and composition in HIV-infected women: an urban cohort. HIV Med. 6(4), 245–252 (2005).
  • Tucker LA, Silvester LJ: Strength training and hypercholesterolemia: an epidemiologic study of 8499 employed men. Am. J. Health Promot. 11(1), 35–41 (1996).
  • Yarasheski KE, Tebas P, Stanerson B et al.: Resistance exercise training reduces hypertriglyceridemia in HIV-infected men treated with antiviral therapy. J. Appl. Physiol. 90(1), 133–138 (2001).
  • Jones SP, Doran DA, Leatt PB, Maher B, Pirmohamed M: Short-term exercise training improves body composition and hyperlipidaemia in HIV-positive individuals with lipodystrophy. AIDS 15(15), 2049–2051 (2001).
  • Stein JH, Wu Y, Kawabata H, Iloeje UH: Increased use of lipid-lowering therapy in patients receiving human immunodeficiency virus protease inhibitors. Am. J. Cardiol. 92(3), 270–274 (2003).
  • Fichtenbaum CJ, Gerber JG, Rosenkranz SL et al.: Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS 16(4), 569–577 (2002).
  • Benesic A, Zilly M, Kluge F et al.: Lipid lowering therapy with fluvastatin and pravastatin in patients with HIV infection and antiretroviral therapy: comparison of efficacy and interaction with indinavir. Infection 32(4), 229–233 (2004).
  • Aberg JA, Rosenkranz SL, Fichtenbaum CJ et al.: Pharmacokinetic interaction between nelfinavir and pravastatin in HIV-seronegative volunteers: ACTG Study A5108. AIDS 20(5), 725–729 (2006).
  • Henry K, Melroe H, Huebesch J, Hermundson J, Simpson J: Atorvastatin and gemfibrozil for protease-inhibitorrelated lipid abnormalities. Lancet 352(9133), 1031–1032 (1998).
  • Calza L, Colangeli V, Manfredi R et al.: Rosuvastatin for the treatment of hyperlipidaemia in HIV-infected patients receiving protease inhibitors: a pilot study. AIDS 19(10), 1103–1105 (2005).
  • Gerber JG, Rosenkranz SL, Fichtenbaum CJ et al.: Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study. J. Acquir. Immune Defic. Syndr. 39(3), 307–312 (2005).
  • del Real G, Jimenez-Baranda S, Mira E et al.: Statins inhibit HIV-1 infection by down-regulating Rho activity. J. Exp. Med. 200(4), 541–547 (2004).
  • Sklar PA, Masur H, Grubb JR et al.: Pravastatin does not have a consistent antiviral effect in chronically HIV-infected individuals on antiretroviral therapy. AIDS 19(10), 1109–1111 (2005).
  • Negredo E, Clotet B, Puig J et al.: The effect of atorvastatin treatment on HIV-1-infected patients interrupting antiretroviral therapy. AIDS 20(4), 619–621 (2006).
  • Manfredi R, Calza L, Chiodo F: Long-term statin use does not act on the temporal trend of CD4 cell count in patients on virologically effective HAART. AIDS 20(3), 455–457 (2006).
  • Coll B, Aragones G, Parra S, Alonso-Villaverde C, Masana L: Ezetimibe effectively decreases LDL-cholesterol in HIV-infected patients. AIDS 20(12), 1675–1677 (2006).
  • Calza L, Manfredi R, Chiodo F: Use of fibrates in the management of hyperlipidemia in HIV-infected patients receiving HAART. Infection 30(1), 26–31 (2002).
  • Calza L, Manfredi R, Chiodo F: Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART. AIDS 17(6), 851–859 (2003).
  • Mastroianni CM, d'Ettorre G, Forcina G et al.: Rhabdomyolysis after cerivastatingemfibrozil therapy in an HIV-infected patient with protease inhibitor-related hyperlipidemia. AIDS 15(6), 820–821 (2001).
  • Aberg JA, Zackin RA, Brobst SW et al.: A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087. AIDS Res. Hum. Retroviruses 21(9), 757–767 (2005).
  • Garg A, Grundy SM. Nicotinic acid as therapy for dyslipidemia in non-insulindependent diabetes mellitus. JAMA 264(6), 723–726 (1990).
  • Gerber MT, Mondy KE, Yarasheski KE et al.: Niacin in HIV-infected individuals with hyperlipidemia receiving potent antiretroviral therapy. Clin. Infect. Dis. 39(3), 419–425 (2004).
  • Eden S, Wiklund O, Oscarsson J, Rosen T, Bengtsson BA: Growth hormone treatment of growth hormone-deficient adults results in a marked increase in Lp(a) and HDL cholesterol concentrations. Arterioscler. Thromb. 13(2), 296–301 (1993).
  • Kotler DP, Muurahainen N, Grunfeld C et al.: Effects of growth hormone on abnormal visceral adipose tissue accumulation and dyslipidemia in HIV-infected patients. J. Acquir. Immune Defic. Syndr. 35(3), 239–252 (2004).
  • D’Amico S, Shi J, Sekhar RV et al.: Physiologic growth hormone replacement improves fasting lipid kinetics in patients with HIV lipodystrophy syndrome. Am. J. Clin. Nutr. 84(1), 204–211 (2006).
  • Martinez E, Conget I, Lozano L, Casamitjana R, Gatell JM: Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS 13(7), 805–810 (1999).
  • Negredo E, Cruz L, Paredes R et al.: Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression. Clin. Infect. Dis. 34(4), 504–510 (2002).
  • Calza L, Manfredi R, Colangeli V et al.: Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia. AIDS 19(10), 1051–1058 (2005).
  • Riddle TM, Kuhel DG, Woollett LA, Fichtenbaum CJ, Hui DY: HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus. J. Biol. Chem. 276(40), 37514–37519 (2001).
  • Hui DY: Effects of HIV protease inhibitor therapy on lipid metabolism. Prog. Lipid Res. 42(2), 81–92 (2003).
  • Fauvel J, Bonnet E, Ruidavets JB et al.: An interaction between apo C-III variants and protease inhibitors contributes to high triglyceride/low HDL levels in treated HIV patients. AIDS 15(18), 2397–2406 (2001).
  • Ordovas JM, Corella D: Nutritional genomics. Annu. Rev. Genomics Hum. Genet. 5, 71–118 (2004).
  • Corella D, Ordovas JM: Single nucleotide polymorphism that influence lipid metabolism: interaction with dietary factors. Annu. Rev. Nutr. 2, 341–390 (2005).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.